A Phase 3 interventional study of CNTO 1959 50 mg and CTNO 1959 100 mg in Psoriasis, sponsored by Janssen Pharmaceutical K.K.. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-22.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 32nd largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2014, is one of 36 in phase 3, and was the 43rd registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).
A Phase 3, multicenter (when more than one hospital or medical school team work on a medical research study), randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know about the study treatment), placebo-controlled (a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect) study of CNTO 1959 (Guselkumab) in the treatment of participants with moderate to severe plaque-type psoriasis. Participants will receive either treatment of CNTO 1959 (guselkumab) 50 milligram (mg) or 100 mg or Placebo 50 mg or 100 mg. Participants will primarily be assessed for Investigator's Global Assessment (IGA) Score and Psoriasis Area and Severity Index (PASI). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
Drug: CNTO 1959 50 mg · Drug: Placebo 100 mg
Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
Drug: CTNO 1959 100 mg · Drug: Placebo 50 mg
Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
Drug: CNTO 1959 50 mg · Drug: CTNO 1959 100 mg · Drug: Placebo 50 mg · Drug: Placebo 100 mg
Participants will receive subcutaneous injection of CNTO 1959 50 mg.
Also known as: Guselkumab
Participants will receive subcutaneous injection of CNTO 1959 100 mg.
Also known as: Guselkumab
Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 16
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.
Time frame: Week 16
Percentage of Participants Who Achieved PASI 75 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
Time frame: Week 16
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Baseline and Week 16
Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 2, 4, 8, 12, and 16
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 2, 4, 8, 12, and 16
Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 2, 4, 8, 12, and 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
Time frame: Weeks 2, 4, 8, 12, and 16
Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percent Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16
Percent Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Time frame: Baseline and Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52
Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16
Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Time frame: Baseline and Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52
Change From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48
BSA as physical measure to define disease severity is to determine how much of the Body Surface Area (BSA) is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
Time frame: Baseline and Week 48
Change From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
Time frame: Baseline and Week 16
Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
Time frame: Baseline and Weeks 28, 36, 48, 52
Percent Change From Baseline in NAPSI Score at Week 16
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
Time frame: Baseline and Week 16
Percent Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
Time frame: Baseline and Weeks 28, 36, 48, 52
Percentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 16
The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
Time frame: Week 16
Percentage of Participants With an Ss-IGA Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Weeks 28, 48 and 52
The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
Time frame: Week 28, 48 and 52
Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 16
The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
Time frame: Week 16
Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 28, 48 and 52
The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
Time frame: Week 28, 48 and 52
Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 8 and 16
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Weeks 8 and 16
Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 28, 36, 48, and 52
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Weeks 28, 36, 48, and 52
Change From Baseline in the DLQI Total Score at Week 8
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Baseline and Weeks 8
Change From Baseline in the DLQI Total Score at Weeks 28, 36, 48, 52
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Baseline and Weeks 28, 36, 48, 52
Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 8 and 16
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Weeks 8 and 16
Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 28, 36, 48, and 52
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Weeks 28, 36, 48, and 52
Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 16
The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline and Week 16
Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Weeks 28 and 48
The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline and Weeks 28, 48
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 16
The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).
Time frame: Baseline and Week 16
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Weeks 28, 48
The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).
Time frame: Baseline and Weeks 28, 48
Change From Baseline in the Physical and Mental Component Summary (PCS and MCS) Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Week 16
SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.
Time frame: Baseline and Week 16
Change From Baseline in the PCS and MCS Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Weeks 28 and 48
SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.
Time frame: Baseline and Weeks 28, 48
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Week 16
Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Week 16 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
Time frame: Baseline and Week 16
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Weeks 28 and 48
Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Weeks 28 and 48 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
Time frame: Baseline and Weeks 28, 48
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 Responses at Weeks 4, 8, and 16
ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
Time frame: Weeks 4, 8, and 16
Percentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 28, 36, 48, and 52
ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
Time frame: Weeks 28, 36, 48, and 52
Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16
Percent change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.
Time frame: Weeks 4, 8, and 16
Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52
Percent change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.
Time frame: Weeks 28, 36, 48, and 52
Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16
Change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.
Time frame: Baseline and Weeks 4, 8, 16
Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52
Change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.
Time frame: Baseline and Weeks 28, 36, 48, 52
Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 4, 8, 16
Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 4, 8 and 16 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 millimeter (mm) (no pain) to 100 mm (the worst pain imaginable).
Time frame: Baseline and Weeks 4, 8, 16
Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 28, 36, 48, 52
Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 28, 36, 48 and 52 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 mm (no pain) to 100 mm (the worst pain imaginable).
Time frame: Baseline and Weeks 28, 36, 48, 52
Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 4, 8, 16
The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 centimeter \[cm\]) to "very poor" (10 cm).
Time frame: Baseline and Weeks 4, 8, 16
Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 28, 36, 48, and 52
The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 cm) to "very poor" (10 cm).
Time frame: Baseline and Weeks 28, 36, 48, 52
Percentage of Participants Who Achieved Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Weeks 4, 8 and 16
HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).
Time frame: Weeks 4, 8, and 16
Percentage of Participants Who Achieved HAQ-DI Response at Weeks 28, 36, 48, 52
HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).
Time frame: Weeks 28, 36, 48, 52
| Milestone | Placebo (Controlled Period [CP]) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|---|
| Started | 64 | 65 | 63 | 0 | 0 |
| Completed | 52 | 63 | 62 | 0 | 0 |
| Not completed | 12 | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 6 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo (Controlled Period [CP]) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|---|
| Started | 0 | 63 | 62 | 26 | 26 |
| Completed | 0 | 60 | 62 | 26 | 25 |
| Not completed | 0 | 3 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | 7.8 | 92.3 | 88.9 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 | 0 | 70.8 | 69.8 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Percentage of Participants Who Achieved PASI 75 Response at Week 16 | 6.3 | 89.2 | 84.1 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -0.8 ± 5.40 | -8.3 ± 5.87 | -8.5 ± 6.95 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 2: IGA 0 responders | 0 | 0 | 0 |
| Week 2: IGA 0/1 responders | 0 | 3.1 | 9.5 |
| Week 2: IGA 0/1/2 responders | 10.9 | 47.7 | 46.0 |
| Week 4: IGA 0 responders | 0 | 1.5 | 6.3 |
| Week 4: IGA 0/1 responders | 1.6 | 27.7 | 25.4 |
| Week 4: IGA 0/1/2 responders | 20.3 | 81.5 | 77.8 |
| Week 8: IGA 0 responders | 0 | 16.9 | 20.6 |
| Week 8: IGA 0/1 responders | 1.6 | 76.9 | 65.1 |
| Week 8: IGA 0/1/2 responders | 20.3 | 93.8 | 93.7 |
| Week 12: IGA 0 responders | 0 | 33.8 | 33.3 |
| Week 12: IGA 0/1 responders | 4.7 | 89.2 | 84.1 |
| Week 12: IGA 0/1/2 responders | 25.0 | 95.4 | 96.8 |
| Week 16: IGA 0 responders | 0 | 44.6 | 44.4 |
| Week 16: IGA 0/1 responders | 7.8 | 92.3 | 88.9 |
| Week 16: IGA 0/1/2 responders | 28.1 | 96.9 | 96.8 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 20: IGA 0 responders | 46.2 | 57.1 | 3.8 | 11.5 |
| Week 20: IGA 0/1 responders | 89.2 | 92.1 | 57.7 | 46.2 |
| Week 20: IGA 0/1/2 responders | 96.9 | 96.8 | 84.6 | 88.5 |
| Week 24: IGA 0 responders | 53.8 | 57.1 | 15.4 | 38.5 |
| Week 24: IGA 0/1 responders | 90.8 | 88.9 | 88.5 | 80.8 |
| Week 24: IGA 0/1/2 responders | 98.5 | 96.8 | 96.2 | 100.0 |
| Week 28: IGA 0 responders | 53.8 | 49.2 | 50.0 | 46.2 |
| Week 28: IGA 0/1 responders | 90.8 | 88.9 | 100.0 | 88.5 |
| Week 28: IGA 0/1/2 responders | 98.5 | 95.2 | 100.0 | 100.0 |
| Week 32: IGA 0 responders | 47.7 | 55.6 | 53.8 | 50.0 |
| Week 32: IGA 0/1 responders | 89.2 | 90.5 | 100.0 | 92.3 |
| Week 32: IGA 0/1/2 responders | 98.5 | 96.8 | 100.0 | 100.0 |
| Week 36: IGA 0 responders | 44.6 | 55.6 | 61.5 | 46.2 |
| Week 36: IGA 0/1 responders | 89.2 | 90.5 | 100.0 | 92.3 |
| Week 36: IGA 0/1/2 responders | 98.5 | 96.8 | 100.0 | 100.0 |
| Week 40: IGA 0 responders | 49.2 | 55.6 | 65.4 | 57.7 |
| Week 40: IGA 0/1 responders | 87.7 | 92.1 | 100.0 | 92.3 |
| Week 40: IGA 0/1/2 responders | 96.9 | 98.4 | 100.0 | 100.0 |
| Week 44: IGA 0 responders | 55.4 | 52.4 | 61.5 | 57.7 |
| Week 44: IGA 0/1 responders | 86.2 | 88.9 | 100.0 | 92.3 |
| Week 44: IGA 0/1/2 responders | 98.5 | 96.8 | 100.0 | 100.0 |
| Week 48: IGA 0 responders | 50.8 | 60.3 | 73.1 | 57.7 |
| Week 48: IGA 0/1 responders | 86.2 | 87.3 | 100.0 | 92.3 |
| Week 48: IGA 0/1/2 responders | 98.5 | 96.8 | 100.0 | 100.0 |
| Week 52: IGA 0 responders | 53.8 | 58.7 | 53.8 | 50.0 |
| Week 52: IGA 0/1 responders | 87.7 | 90.5 | 100.0 | 88.5 |
| Week 52: IGA 0/1/2 responders | 98.5 | 98.4 | 100.0 | 100.0 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 2: PASI 50 responders | 0 | 4.6 | 17.5 |
| Week 2: PASI 75 responders | 0 | 0 | 1.6 |
| Week 2: PASI 90 responders | 0 | 0 | 0 |
| Week 2: PASI 100 responders | 0 | 0 | 0 |
| Week 4: PASI 50 responders | 1.6 | 49.2 | 49.2 |
| Week 4: PASI 75 responders | 0 | 15.4 | 17.5 |
| Week 4: PASI 90 responders | 0 | 4.6 | 4.8 |
| Week 4: PASI 100 responders | 0 | 1.5 | 1.6 |
| Week 8: PASI 50 responders | 9.4 | 87.7 | 79.4 |
| Week 8: PASI 75 responders | 0 | 55.4 | 50.8 |
| Week 8: PASI 90 responders | 0 | 30.8 | 30.2 |
| Week 8: PASI 100 responders | 0 | 7.7 | 7.9 |
| Week 12: PASI 50 responders | 7.8 | 90.8 | 92.1 |
| Week 12: PASI 75 responders | 3.1 | 78.5 | 79.4 |
| Week 12: PASI 90 responders | 0 | 47.7 | 38.1 |
| Week 12: PASI 100 responders | 0 | 16.9 | 22.2 |
| Week 16: PASI 50 responders | 14.1 | 93.8 | 95.2 |
| Week 16: PASI 75 responders | 6.3 | 89.2 | 84.1 |
| Week 16: PASI 90 responders | 0 | 70.8 | 69.8 |
| Week 16: PASI 100 responders | 0 | 32.3 | 27.0 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 20: PASI 50 responders | 95.4 | 96.8 | 57.7 | 65.4 |
| Week 20: PASI 75 responders | 90.8 | 88.9 | 46.2 | 30.8 |
| Week 20: PASI 90 responders | 70.8 | 71.4 | 19.2 | 15.4 |
| Week 20: PASI 100 responders | 33.8 | 34.9 | 3.8 | 0 |
| Week 24: PASI 50 responders | 98.5 | 98.4 | 92.3 | 84.6 |
| Week 24: PASI 75 responders | 90.8 | 90.5 | 80.8 | 61.5 |
| Week 24: PASI 90 responders | 78.5 | 76.2 | 42.3 | 46.2 |
| Week 24: PASI 100 responders | 41.5 | 44.4 | 11.5 | 23.1 |
| Week 28: PASI 50 responders | 98.5 | 98.4 | 100.0 | 92.3 |
| Week 28: PASI 75 responders | 92.3 | 90.5 | 88.5 | 80.8 |
| Week 28: PASI 90 responders | 75.4 | 77.8 | 73.1 | 61.5 |
| Week 28: PASI 100 responders | 44.6 | 38.1 | 30.8 | 34.6 |
| Week 32: PASI 50 responders | 98.5 | 98.4 | 100.0 | 96.2 |
| Week 32: PASI 75 responders | 92.3 | 90.5 | 92.3 | 84.6 |
| Week 32: PASI 90 responders | 76.9 | 76.2 | 76.9 | 69.2 |
| Week 32: PASI 100 responders | 41.5 | 44.4 | 34.6 | 38.5 |
| Week 36: PASI 50 responders | 98.5 | 95.2 | 100.0 | 96.2 |
| Week 36: PASI 75 responders | 92.3 | 90.5 | 96.2 | 92.3 |
| Week 36: PASI 90 responders | 78.5 | 76.2 | 84.6 | 65.4 |
| Week 36: PASI 100 responders | 36.9 | 42.9 | 30.8 | 42.3 |
| Week 40: PASI 50 responders | 98.5 | 98.4 | 100.0 | 96.2 |
| Week 40: PASI 75 responders | 90.8 | 90.5 | 100.0 | 92.3 |
| Week 40: PASI 90 responders | 78.5 | 77.8 | 96.2 | 73.1 |
| Week 40: PASI 100 responders | 33.8 | 44.4 | 38.5 | 50.0 |
| Week 44: PASI 50 responders | 98.5 | 95.2 | 100.0 | 96.2 |
| Week 44: PASI 75 responders | 90.8 | 88.9 | 100.0 | 92.3 |
| Week 44: PASI 90 responders | 80.0 | 74.6 | 88.5 | 73.1 |
| Week 44: PASI 100 responders | 38.5 | 44.4 | 42.3 | 50.0 |
| Week 48: PASI 50 responders | 98.5 | 96.8 | 100.0 | 96.2 |
| Week 48: PASI 75 responders | 90.8 | 93.7 | 100.0 | 92.3 |
| Week 48: PASI 90 responders | 75.4 | 77.8 | 100.0 | 76.9 |
| Week 48: PASI 100 responders | 36.9 | 49.2 | 46.2 | 42.3 |
| Week 52: PASI 50 responders | 98.5 | 98.4 | 100.0 | 96.2 |
| Week 52: PASI 75 responders | 92.3 | 90.5 | 100.0 | 92.3 |
| Week 52: PASI 90 responders | 75.4 | 77.8 | 92.3 | 73.1 |
| Week 52: PASI 100 responders | 38.5 | 47.6 | 38.5 | 42.3 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
| percent change | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 2 | 0.4 ± 18.55 | 20.1 ± 20.85 | 23.6 ± 23.76 |
| Week 4 | 0.0 ± 27.74 | 45.3 ± 26.72 | 44.9 ± 30.80 |
| Week 8 | 1.5 ± 32.73 | 74.5 ± 22.39 | 70.3 ± 25.42 |
| Week 12 | 0.5 ± 38.28 | 83.7 ± 20.00 | 82.9 ± 18.56 |
| Week 16 | 0.2 ± 45.53 | 88.9 ± 17.34 | 88.7 ± 17.77 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
| percent change | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 20 | 89.4 ± 18.21 | 90.6 ± 16.45 | 58.7 ± 33.67 | 51.9 ± 39.06 |
| Week 24 | 91.6 ± 14.59 | 92.1 ± 15.51 | 80.7 ± 24.87 | 78.8 ± 22.44 |
| Week 28 | 91.9 ± 14.05 | 91.4 ± 16.24 | 91.6 ± 10.81 | 85.6 ± 20.60 |
| Week 32 | 92.5 ± 12.38 | 92.0 ± 15.78 | 93.1 ± 8.59 | 89.1 ± 19.66 |
| Week 36 | 92.2 ± 13.42 | 90.5 ± 19.40 | 94.7 ± 6.76 | 91.5 ± 13.84 |
| Week 40 | 92.3 ± 13.86 | 92.1 ± 15.86 | 96.4 ± 3.87 | 92.3 ± 14.08 |
| Week 44 | 91.8 ± 17.30 | 91.1 ± 17.26 | 96.6 ± 4.39 | 92.2 ± 14.28 |
| Week 48 | 91.5 ± 17.28 | 92.1 ± 16.14 | 97.9 ± 2.73 | 91.8 ± 14.21 |
| Week 52 | 91.6 ± 17.12 | 92.5 ± 15.39 | 96.7 ± 4.45 | 91.4 ± 14.02 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 2 | 0.0 ± 4.44 | -5.7 ± 7.13 | -6.3 ± 7.17 |
| Week 4 | -0.2 ± 7.13 | -12.1 ± 10.55 | -12.5 ± 11.00 |
| Week 8 | -1.0 ± 8.99 | -19.1 ± 10.62 | -19.2 ± 11.80 |
| Week 12 | -0.6 ± 10.62 | -21.4 ± 11.11 | -22.4 ± 11.86 |
| Week 16 | -0.5 ± 12.39 | -22.6 ± 11.00 | -23.9 ± 12.27 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 20 | -22.8 ± 11.23 | -24.3 ± 12.52 | -18.3 ± 15.46 | -11.3 ± 10.33 |
| Week 24 | -23.4 ± 11.16 | -24.7 ± 12.35 | -24.2 ± 15.12 | -18.2 ± 9.56 |
| Week 28 | -23.6 ± 11.44 | -24.5 ± 12.56 | -27.0 ± 14.84 | -20.1 ± 10.52 |
| Week 32 | -23.7 ± 11.30 | -24.7 ± 12.58 | -27.6 ± 15.02 | -21.0 ± 11.05 |
| Week 36 | -23.6 ± 11.38 | -24.3 ± 12.72 | -28.0 ± 15.02 | -21.5 ± 10.37 |
| Week 40 | -23.7 ± 11.51 | -24.6 ± 12.29 | -28.4 ± 14.96 | -21.7 ± 10.65 |
| Week 44 | -23.5 ± 11.69 | -24.3 ± 12.29 | -28.5 ± 15.04 | -21.6 ± 10.55 |
| Week 48 | -23.4 ± 11.59 | -24.6 ± 12.27 | -28.7 ± 14.90 | -21.6 ± 10.78 |
| Week 52 | -23.5 ± 11.74 | -24.6 ± 12.11 | -28.5 ± 15.07 | -21.5 ± 10.62 |
BSA as physical measure to define disease severity is to determine how much of the Body Surface Area (BSA) is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
| Change in BSA (% points) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Change From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48 | -31.7 ± 22.40 | -34.4 ± 21.19 | -37.1 ± 22.24 | -27.7 ± 16.08 |
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Change From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16 | -0.2 ± 1.13 | -1.2 ± 1.61 | -1.5 ± 1.78 |
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | -2.2 ± 1.79 | -2.4 ± 2.34 | -1.7 ± 1.40 | -0.7 ± 1.13 |
| Week 36 | -2.3 ± 2.01 | -2.7 ± 2.23 | -2.5 ± 1.77 | -1.2 ± 1.50 |
| Week 48 | -2.7 ± 1.91 | -2.7 ± 2.44 | -3.3 ± 2.22 | -1.7 ± 1.75 |
| Week 52 | -2.8 ± 1.94 | -2.7 ± 2.20 | -3.3 ± 2.34 | -1.4 ± 1.54 |
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
| percent change | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Percent Change From Baseline in NAPSI Score at Week 16 | 1.0 ± 59.38 | 31.6 ± 43.56 | 39.1 ± 48.93 |
NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).
| percent change | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 57.9 ± 42.99 | 61.1 ± 43.15 | 48.7 ± 38.77 | 23.6 ± 49.69 |
| Week 36 | 59.6 ± 46.95 | 67.4 ± 45.44 | 69.9 ± 30.48 | 38.4 ± 40.34 |
| Week 48 | 71.0 ± 37.11 | 68.1 ± 49.01 | 80.2 ± 23.06 | 53.7 ± 42.99 |
| Week 52 | 74.4 ± 35.11 | 75.3 ± 41.32 | 79.2 ± 25.62 | 44.9 ± 53.56 |
The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Percentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 16 | 10.5 | 74.1 | 82.8 |
The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 86.2 | 86.2 | 90.5 | 70.8 |
| Week 48 | 84.5 | 84.5 | 85.7 | 83.3 |
| Week 52 | 84.5 | 86.2 | 85.7 | 95.8 |
The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Absence of Disease (0) | 3.5 | 48.3 | 63.8 |
| Very Mild Disease (1) | 8.8 | 41.4 | 22.4 |
| Mild Disease (2) | 21.1 | 8.6 | 8.6 |
| Moderate Disease (3) | 49.1 | 1.7 | 5.2 |
| Severe Disease (4) | 17.5 | 0 | 0 |
The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: Absence of Disease (0) | 63.8 | 70.7 | 66.7 | 50.0 |
| Week 28: Very Mild Disease (1) | 31.0 | 22.4 | 28.6 | 25.0 |
| Week 28: Mild Disease (2) | 3.4 | 3.4 | 4.8 | 12.5 |
| Week 28: Moderate Disease (3) | 1.7 | 3.4 | 0 | 12.5 |
| Week 28: Severe Disease (4) | 0 | 0 | 0 | 0 |
| Week 48: Absence of Disease (0) | 67.2 | 75.9 | 76.2 | 66.7 |
| Week 48: Very Mild Disease (1) | 25.9 | 13.8 | 9.5 | 20.8 |
| Week 48: Mild Disease (2) | 5.2 | 6.9 | 9.5 | 12.5 |
| Week 48: Moderate Disease (3) | 1.7 | 3.4 | 4.8 | 0 |
| Week 48: Severe Disease (4) | 0 | 0 | 0 | 0 |
| Week 52: Absence of Disease (0) | 67.2 | 77.6 | 66.7 | 75.0 |
| Week 52: Very Mild Disease (1) | 27.6 | 10.3 | 19.0 | 20.8 |
| Week 52: Mild Disease (2) | 3.4 | 10.3 | 14.3 | 4.2 |
| Week 52: Moderate Disease (3) | 1.7 | 1.7 | 0 | 0 |
| Week 52: Severe Disease (4) | 0 | 0 | 0 | 0 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 8 | 6.6 | 43.8 | 43.3 |
| Week 16 | 6.6 | 64.1 | 68.3 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 70.3 | 75.0 | 50.0 | 68.0 |
| Week 36 | 79.7 | 83.3 | 79.2 | 68.0 |
| Week 48 | 73.4 | 73.3 | 62.5 | 72.0 |
| Week 52 | 73.4 | 76.7 | 75.0 | 80.0 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Change From Baseline in the DLQI Total Score at Week 8 | -0.4 ± 4.71 | -7.5 ± 5.28 | -7.0 ± 6.35 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | -9.0 ± 5.85 | -8.9 ± 6.95 | -9.5 ± 7.73 | -5.5 ± 5.19 |
| Week 36 | -9.2 ± 6.44 | -9.2 ± 7.27 | -10.3 ± 8.01 | -6.1 ± 5.99 |
| Week 48 | -9.2 ± 6.20 | -9.1 ± 7.12 | -10.1 ± 7.94 | -6.1 ± 5.82 |
| Week 52 | -9.2 ± 6.39 | -9.0 ± 7.28 | -10.1 ± 7.79 | -6.5 ± 5.05 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 8 | 17.2 | 61.5 | 58.7 |
| Week 16 | 20.3 | 67.7 | 69.8 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 69.2 | 73.0 | 65.4 | 57.7 |
| Week 36 | 72.3 | 68.3 | 69.2 | 57.7 |
| Week 48 | 72.3 | 71.4 | 69.2 | 61.5 |
| Week 52 | 72.3 | 71.4 | 69.2 | 61.5 |
The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 16 | 0.05 ± 0.141 | 0.20 ± 0.199 | 0.18 ± 0.210 |
The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 0.20 ± 0.187 | 0.20 ± 0.221 | 0.25 ± 0.170 | 0.14 ± 0.133 |
| Week 48 | 0.20 ± 0.198 | 0.21 ± 0.228 | 0.28 ± 0.152 | 0.15 ± 0.140 |
The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 16 | 2.45 ± 22.440 | 21.20 ± 23.542 | 18.43 ± 26.206 |
The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 22.94 ± 24.759 | 20.87 ± 26.465 | 20.73 ± 20.095 | 11.62 ± 26.831 |
| Week 48 | 20.88 ± 29.647 | 21.70 ± 26.577 | 20.38 ± 22.094 | 7.00 ± 29.490 |
SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| PCS | 0.3 ± 9.90 | 7.4 ± 15.65 | 7.3 ± 14.40 |
| MCS | 1.3 ± 8.21 | 4.0 ± 7.22 | 5.3 ± 9.63 |
SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: PCS | 7.7 ± 13.71 | 8.9 ± 14.83 | 6.4 ± 10.20 | 5.4 ± 9.80 |
| Week 48: PCS | 8.2 ± 14.22 | 8.4 ± 15.16 | 8.8 ± 12.13 | 4.4 ± 7.60 |
| Week 28: MCS | 5.9 ± 9.62 | 4.6 ± 10.30 | 6.5 ± 6.91 | 4.9 ± 9.83 |
| Week 48: MCS | 5.7 ± 9.04 | 5.6 ± 9.32 | 4.5 ± 9.92 | 5.0 ± 11.00 |
Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Week 16 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
| units on a scale | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Absenteeism | 0.9 ± 14.96 | -2.4 ± 8.14 | -1.9 ± 8.18 |
| Activity Impairment | -7.7 ± 24.09 | -30.9 ± 31.95 | -33.8 ± 33.91 |
| Presenteeism | -7.2 ± 22.62 | -22.0 ± 34.06 | -23.7 ± 30.92 |
| Work Productivity Loss | -7.6 ± 23.24 | -23.0 ± 34.38 | -24.1 ± 31.79 |
Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Weeks 28 and 48 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
| units on a scale | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: Absenteeism | -3.0 ± 10.93 | -2.8 ± 9.12 | -4.0 ± 8.78 | -0.1 ± 2.03 |
| Week 28: Activity Impairment | -35.1 ± 32.02 | -33.5 ± 32.19 | -32.7 ± 29.20 | -28.1 ± 28.85 |
| Week 28: Presenteeism | -26.9 ± 30.83 | -24.5 ± 34.43 | -27.1 ± 25.62 | -18.7 ± 26.85 |
| Week 28: Work Productivity Loss | -28.1 ± 31.18 | -25.1 ± 35.05 | -28.3 ± 26.61 | -18.3 ± 26.68 |
| Week 48: Absenteeism | -2.0 ± 6.56 | -2.9 ± 9.37 | -4.5 ± 9.02 | 0.7 ± 2.49 |
| Week 48: Activity Impairment | -38.0 ± 30.58 | -36.8 ± 31.72 | -36.2 ± 28.44 | -25.0 ± 30.50 |
| Week 48: Presenteeism | -29.3 ± 31.25 | -30.8 ± 30.97 | -30.0 ± 29.93 | -20.4 ± 27.88 |
| Week 48: Work Productivity Loss | -29.6 ± 31.88 | -31.4 ± 31.71 | -31.5 ± 30.93 | -19.2 ± 27.84 |
ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4: ACR 20 responders | 0 | 27.3 | 10.0 |
| Week 4: ACR 50 responders | 0 | 18.2 | 0 |
| Week 4: ACR 70 responders | 0 | 9.1 | 0 |
| Week 8: ACR 20 responders | 10.0 | 45.5 | 20.0 |
| Week 8: ACR 50 responders | 0 | 36.4 | 20.0 |
| Week 8: ACR 70 responders | 0 | 18.2 | 0 |
| Week 16: ACR 20 responders | 0 | 45.5 | 30.0 |
| Week 16: ACR 50 responders | 0 | 18.2 | 30.0 |
| Week 16: ACR 70 responders | 0 | 9.1 | 30.0 |
ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: ACR 20 responders | 36.4 | 40.0 | 66.7 | 0 |
| Week 28: ACR 50 responders | 27.3 | 40.0 | 33.3 | 0 |
| Week 28: ACR 70 responders | 18.2 | 30.0 | 33.3 | 0 |
| Week 36: ACR 20 responders | 45.5 | 40.0 | 66.7 | 50.0 |
| Week 36: ACR 50 responders | 36.4 | 40.0 | 66.7 | 25.0 |
| Week 36: ACR 70 responders | 27.3 | 40.0 | 33.3 | 0 |
| Week 48: ACR 20 responders | 45.5 | 30.0 | 66.7 | 25.0 |
| Week 48: ACR 50 responders | 45.5 | 30.0 | 66.7 | 25.0 |
| Week 48: ACR 70 responders | 36.4 | 30.0 | 66.7 | 0 |
| Week 52: ACR 20 responders | 54.5 | 20.0 | 66.7 | 50.0 |
| Week 52: ACR 50 responders | 36.4 | 20.0 | 66.7 | 50.0 |
| Week 52: ACR 70 responders | 27.3 | 20.0 | 66.7 | 0 |
Percent change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.
| percent change | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4: Tender joints | -7.4 ± 22.22 | 41.1 ± 34.47 | -8.8 ± 117.56 |
| Week 4: Swollen joints | 14.1 ± 35.00 | 20.5 ± 39.50 | 22.2 ± 32.77 |
| Week 8: Tender joints | -54.6 ± 188.70 | 47.3 ± 39.61 | 50.1 ± 58.06 |
| Week 8: Swollen joints | 29.5 ± 39.76 | 56.0 ± 42.33 | 50.0 ± 40.82 |
| Week 16: Tender joints | -60.2 ± 86.58 | 47.0 ± 40.12 | 22.7 ± 126.76 |
| Week 16: Swollen joints | 22.7 ± 52.66 | 55.7 ± 46.71 | 79.2 ± 40.05 |
Percent change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.
| percent change | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: Tender joints | 54.9 ± 41.34 | 60.6 ± 46.80 | 33.3 ± 76.38 | -100.0 ± 81.65 |
| Week 28: Swollen joint | 66.0 ± 39.14 | 94.4 ± 8.61 | 66.1 ± 29.36 | 43.3 ± 60.28 |
| Week 36: Tender joints | 69.7 ± 40.66 | 62.1 ± 47.33 | 33.3 ± 76.38 | 25.0 ± 95.74 |
| Week 36: Swollen joint | 55.2 ± 64.82 | 94.4 ± 13.61 | 84.7 ± 16.84 | 63.3 ± 32.15 |
| Week 48: Tender joints | 53.9 ± 61.03 | 45.4 ± 73.14 | 50.0 ± 86.60 | 25.0 ± 95.74 |
| Week 48: Swollen joint | 72.4 ± 42.84 | 80.6 ± 34.02 | 82.8 ± 13.98 | 70.0 ± 26.46 |
| Week 52: Tender joints | 67.8 ± 47.31 | 32.9 ± 72.40 | 66.7 ± 57.74 | 75.0 ± 50.00 |
| Week 52: Swollen joint | 84.5 ± 32.70 | 58.3 ± 55.53 | 88.9 ± 19.25 | 86.7 ± 23.09 |
Change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.
| joints | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4: Tender joints | 0.2 ± 0.63 | -3.8 ± 6.15 | -1.6 ± 4.74 |
| Week 4: Swollen joints | -0.4 ± 0.97 | -1.2 ± 2.44 | -0.4 ± 1.58 |
| Week 8: Tender joints | 0.9 ± 3.38 | -4.9 ± 9.24 | -2.6 ± 4.79 |
| Week 8: Swollen joints | -1.9 ± 4.68 | -2.1 ± 2.55 | -2.2 ± 3.43 |
| Week 16: Tender joints | 1.3 ± 2.06 | -3.9 ± 6.32 | -3.3 ± 5.17 |
| Week 16: Swollen joints | -1.3 ± 3.56 | -2.3 ± 3.41 | -3.2 ± 4.37 |
Change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.
| joints | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28: Tender joints | -4.0 ± 6.03 | -4.1 ± 5.93 | -1.0 ± 2.00 | 1.8 ± 1.71 |
| Week 28: Swollen joint | -2.5 ± 2.81 | -3.4 ± 4.35 | -9.7 ± 8.02 | -0.3 ± 0.96 |
| Week 36: Tender joints | -3.8 ± 6.23 | -4.0 ± 5.08 | -1.0 ± 2.00 | -1.0 ± 2.16 |
| Week 36: Swollen joint | -2.8 ± 3.46 | -3.6 ± 4.79 | -11.7 ± 8.62 | -1.0 ± 0.82 |
| Week 48: Tender joints | -3.3 ± 7.18 | -3.0 ± 4.83 | -1.3 ± 2.08 | -1.0 ± 2.16 |
| Week 48: Swollen joint | -2.9 ± 3.30 | -2.5 ± 3.87 | -11.7 ± 9.29 | -1.3 ± 1.26 |
| Week 52: Tender joints | -7.0 ± 11.19 | -2.9 ± 4.58 | -1.7 ± 1.53 | -1.5 ± 1.73 |
| Week 52: Swollen joint | -3.2 ± 3.43 | -1.5 ± 4.09 | -12.7 ± 10.26 | -1.5 ± 1.29 |
Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 4, 8 and 16 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 millimeter (mm) (no pain) to 100 mm (the worst pain imaginable).
| percent change | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4 | 13.70 ± 23.698 | 3.99 ± 78.918 | 10.32 ± 118.053 |
| Week 8 | 2.36 ± 37.869 | 38.19 ± 43.951 | 45.15 ± 55.679 |
| Week 16 | -0.73 ± 33.066 | 45.51 ± 34.419 | 62.11 ± 41.719 |
Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 28, 36, 48 and 52 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 mm (no pain) to 100 mm (the worst pain imaginable).
| Percent change | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | -37.67 ± 339.724 | 73.28 ± 28.687 | 51.18 ± 30.418 | 40.96 ± 73.340 |
| Week 36 | -26.65 ± 273.745 | 68.21 ± 40.538 | 71.92 ± 21.156 | 47.37 ± 46.079 |
| Week 48 | 50.38 ± 74.874 | 57.65 ± 34.861 | 81.36 ± 12.019 | 74.08 ± 14.330 |
| Week 52 | -30.54 ± 305.279 | 62.09 ± 40.678 | 77.06 ± 23.487 | 61.47 ± 67.467 |
The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 centimeter \[cm\]) to "very poor" (10 cm).
| percent change | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4 | 12.55 ± 24.547 | 39.64 ± 38.514 | 58.81 ± 29.281 |
| Week 8 | 2.50 ± 34.402 | 44.50 ± 39.328 | 63.10 ± 42.085 |
| Week 16 | -6.52 ± 28.037 | 21.38 ± 71.545 | 75.70 ± 34.106 |
The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 cm) to "very poor" (10 cm).
| percent change | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | -46.83 ± 346.499 | 71.26 ± 35.552 | 45.85 ± 35.019 | 61.23 ± 16.062 |
| Week 36 | -48.87 ± 341.563 | 75.55 ± 33.992 | 51.95 ± 27.007 | 54.46 ± 27.386 |
| Week 48 | 43.09 ± 109.254 | 58.36 ± 41.137 | 76.02 ± 24.470 | 67.60 ± 20.616 |
| Week 52 | -20.17 ± 298.482 | 66.00 ± 36.151 | 71.59 ± 34.140 | 69.10 ± 47.796 |
HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).
| percentage of participants | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) |
|---|---|---|---|
| Week 4 | 10.0 | 36.4 | 10.0 |
| Week 8 | 20.0 | 45.5 | 20.0 |
| Week 16 | 0 | 54.5 | 30.0 |
HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).
| percentage of participants | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|
| Week 28 | 45.5 | 30.0 | 66.7 | 25.0 |
| Week 36 | 54.5 | 30.0 | 66.7 | 0 |
| Week 48 | 45.5 | 20.0 | 66.7 | 25.0 |
| Week 52 | 45.5 | 10.0 | 66.7 | 25.0 |
Collected over Up to Week 52. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (CP) | — | 2/64 (3.1%) | 36/64 (56.3%) |
| Guselkumab 50 mg (CP) | — | 1/65 (1.5%) | 27/65 (41.5%) |
| Guselkumab 100 mg (CP) | — | 1/63 (1.6%) | 26/63 (41.3%) |
| Guselkumab 50 mg (After CP) | — | 6/63 (9.5%) | 56/63 (88.9%) |
| Guselkumab 100 mg (After CP) | — | 6/62 (9.7%) | 55/62 (88.7%) |
| Placebo to Guselkumab 50 mg (After CP) | — | 4/26 (15.4%) | 25/26 (96.2%) |
| Placebo to Guselkumab 100 mg (After CP) | — | 5/26 (19.2%) | 26/26 (100%) |
| Event | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Guselkumab 50 mg (After CP) | Guselkumab 100 mg (After CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|---|---|---|
| Atrial FibrillationCardiac disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 1/26 | 0/26 |
| Cardiac Failure CongestiveCardiac disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 1/26 | 0/26 |
| CataractEye disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 0/26 | 1/26 |
| Diabetic RetinopathyEye disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 0/26 | 1/26 |
| GlaucomaEye disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 0/26 | 1/26 |
| Macular HoleEye disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 0/26 | 1/26 |
| Vitreous HaemorrhageEye disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 0/26 | 1/26 |
| Gastric PerforationGastrointestinal disorders | 0/64 | 0/65 | 0/63 | 0/63 | 0/62 | 1/26 | 0/26 |
| Inguinal HerniaGastrointestinal disorders | 0/64 | 0/65 | 0/63 | 1/63 | 0/62 | 1/26 | 0/26 |
| Large Intestine PolypGastrointestinal disorders | 0/64 | 0/65 | 0/63 | 0/63 | 1/62 | 0/26 | 1/26 |
| Event | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Guselkumab 50 mg (After CP) | Guselkumab 100 mg (After CP) | Placebo to Guselkumab 50 mg (After CP) | Placebo to Guselkumab 100 mg (After CP) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/64 | 14/65 | 8/63 | 38/63 | 31/62 | 14/26 | 14/26 |
| Dental CariesGastrointestinal disorders | 1/64 | 1/65 | 2/63 | 4/63 | 5/62 | 6/26 | 2/26 |
| BronchitisInfections and infestations | 1/64 | 0/65 | 0/63 | 2/63 | 5/62 | 0/26 | 6/26 |
| InfluenzaInfections and infestations | 1/64 | 1/65 | 0/63 | 9/63 | 3/62 | 5/26 | 5/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/64 | 0/65 | 0/63 | 5/63 | 2/62 | 3/26 | 5/26 |
| EczemaSkin and subcutaneous tissue disorders | 1/64 | 0/65 | 0/63 | 3/63 | 7/62 | 3/26 | 5/26 |
| HypertensionVascular disorders | 2/64 | 2/65 | 0/63 | 7/63 | 6/62 | 5/26 | 5/26 |
| PsoriasisSkin and subcutaneous tissue disorders | 11/64 | 0/65 | 0/63 | 0/63 | 2/62 | 0/26 | 1/26 |
| Injection Site ErythemaGeneral disorders | 1/64 | 0/65 | 0/63 | 5/63 | 7/62 | 3/26 | 4/26 |
| Diabetes MellitusMetabolism and nutrition disorders | 1/64 | 1/65 | 0/63 | 1/63 | 6/62 | 0/26 | 4/26 |
| Age, Continuous(years) | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Total |
|---|---|---|---|---|
| Mean | 48.3 ± 10.56 | 50.1 ± 12.66 | 47.8 ± 11.07 | 48.8 ± 11.46 |
| Sex: Female, Male(Participants) | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Total |
|---|---|---|---|---|
| Female | 10 | 21 | 16 | 47 |
| Male | 54 | 44 | 47 | 145 |
| Region of Enrollment(Participants) | Placebo (CP) | Guselkumab 50 mg (CP) | Guselkumab 100 mg (CP) | Total |
|---|---|---|---|---|
| Japan | 64 | 65 | 63 | 192 |
Ran from Dec 2014 to primary completion in Mar 2016, 14 months.
Results were first posted in May 2020, 4 years 2 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab